SCOPE Joint Action Work Package 8



Strengthening capabilities for benefit risk assessment Jelena Ivanovic – WP8, AIFA IT

20 March 2017 London





- Ensuring that regulators can respond to emerging or urgent health issues in a timely and efficient way is a key deliverable of the pharmacovigilance (PV) legislation.
- The individual Member States (MS) of the EEA power the entire PV system and provide much of the resource and knowledge for assessing safety issues.
- The updating of the medicines B/R profiles throughout the lifecycle represents **one of the most challenging and** at the same time **most important tasks of the PV system.**





Maximising B/R Assessment in PV



• There is a need for an increase in collaboration among stakeholders:

✓ to augment the provision of data to accurately weigh the evolving B/R balance and to enhance review capability

✓ challenges to accrue information on a medicine's benefits after approval
✓ PM benefit-risk evaluationis are mainly influenced by additional safety information


• Expectations on regulatory Authorities

Why and how did we make decisions?

Have we been consistent?

Why is it sometimes different from what is expected?

What is the evidence for regulatory decisions?



B/R assessment in the post-approval period; CIRS Workshop report,12-13 june 2014


European Union's new pharmacovigilance legislation

- The importance of consistency structured, sustainable and systematic process is fundamental in assisting and improving decision making and facilitates communication.
- Each National Competent Authority (NCA) may come from a different perspective but a consistency in a B/R assessment is of particular importance for the EU PV network.



SCOPE





Source: Franck Diafouka, EMA, PCWP and HCPWG Joint Meeting

Key WP8 target are PV/clinical multitasking assessors:

- Identifying benefits and risks
- Assessing benefits and risks
- ✓ Interpretation and recommendation
- Processes must be transparent, documented and communicated

 a good ability for integrating data from multiple sources

SCOPE


- ✓ the estimation of uncertainty
- ✓ ability to handle multiple objectives, differences in perspectives/positions etc.
- ability to work in a team and to adhere to proposed timeframes
 - a good coordination with other participants and stakeholders in the process etc

benefit-risk evaluators often need to learn from prior decisions and experiences

Procedures on the PRAC Agenda



Number of items on PRAC agenda



REPORT FROM THE COMMISSION - Pharmacovigilance related activities of Member States and the European Medicines Agency concerning medicinal products for human use (2012 – 2014)

WP8 Aims



In 2013 we started our work following specific objectives **to promote consistency in PV procedures assessment** throughout the lifecycle:

✓ To collect information on existing methods and processes for PV assessments and deliver a report on good practices useful for NCAs in operating PV effectively and to support the PRAC in its work;

✓ To develop a competency framework in support of PV for human medicinal products throughout the lifecycle: WP8 topics
Recommendations, Practical guides and Training programme;


✓ To identify and further elaborate appropriate training materials to assist NCAs to develop/improve their processes and to maximise training opportunities for PV assessors (e.g e-learning modules).



SCOPE

Coordination (IT lead) AC: ES, GR, IE, NL, NO, PT, SE, UK


Topic 1: IT lead; AC: ES, GR, IE, NL, NO, SE, UK **Identification of available data sources outside spontaneous reports**



AC: Active contributors

WP8: Progress and main deliverables






WP8 Survey



- Conducted from 4th July to 3rd November 2014 and a high response rate of 90% - 25 MS (3 MS are not official SCOPE partners) was obtained to all five surveys
- All but one of the respondents include RMP, PSUR, referral assessment, evaluation of PASS protocols within their institution's responsibilities

Figure 1. Response rate per month during the surveys:



WP8: Key survey findings Topic 2 - RMPs




The current practice of assessment of RMPs - focus on challenges, possible solutions and good assessment practices.

- **Collaboration** as key element pre-clinical/clinical/PV assessors
 - ✓ 87% have this possibility

Quality of assessment

- ✓ 60% peer reviewers within agency
- ✓ 45% internal meetings
- ✓ 35% checklists



- A "key challenges" areas where more guidance is needed
 - Safety spec differentiation between important/not important and identified/potential safety concerns
 - PhV Plan the need for additional studies and design of studies
 - Risk Min Plan the need for additional risk minimization and best suitable measures - RMPs for generic products – consistency

WP8: Key survey findings Topic 3 - PASS



- 21/25 (84%) reported having had experience in evaluating PASS protocols
- 20/21 use GVP module VIII as a guideline half (11/21) use EnCEPP checklist
- Joint assessment considered to be important
- PV assessors , clinical and pharmaco-epidemiology assessors are mainly involved
- 19/24 consider a general epidemiology support function should be available
- The mainstay in training is **senior PV assessors acting as mentors**
- Only a limited number of NCAs mentioned some **form of regular training** program for assessors in this field

Challenging factors in the assessment



	Response Percent	Response Count
Adherence to obligation	30%	6
Assessment of data sources	40%	8
More complex study designs	<mark>75%</mark>	15
Sample size estimates	35%	7
Analytical strategies	40%	8
Overall feasibility	<mark>65%</mark>	13
Promotional aspects	<mark>50%</mark>	10
Quality assurance procedures	10%	2
Total responses		20

WP8: Key survey findings Topic 4 – PSURs and referrals



Practices for the B/R evaluation – the specific tools

Table 1. Specific tools or methods in use facilitating the B/R decision and assessment process

Answer Options	Response	Response
	(%)	n.
Follow templates/ please describe	87	7
Checklists, please describe	62	5
Decision algorithms, please describe	37	3
EMA Effects Table, please describe	37	3
Tables, please describe	37	3
Mathematical models, please describe	25	2
Other, please describe	12	1
answered question		8
skipped question		17

WP8: Key survey findings Topic 4 – PSURs



 10 out of 24 NCAs had experience with procedure (54 % have an internal SOP) before the closure of the survey (November 2014) and identified challenges and solutions for the assessment of PSUSAs:

PSUSA – Lots of PSURs

Discussion of signal in a generic PSUR only



Complex procedures and require time for assessment depending on numbers of PSURs and the data there in

Issues associated with advent of PSUSA procedures e.g. late submissions, lack of awareness of process

WP8: Key survey findings Topic 4 –referrals



Questions:

- 1. Use of **external** guidance/templates
 - 50% use guidance
- 2. Use of internal guidance
 - 74% have no SOP but limited experience to date
- 3. Use and benefits of planning meetings
 - 70% consider to be useful tools
- 4. Approach to assessment of MAH responses
- 5. Assessment report review

Complexity of referrals and limited experience supports development of additional guidance




Main challenges identified



- Unfocussed/extensive list of questions
- ✓ Challenging timelines
- Late MAH submissions
- ✓ Unsatisfactory MAH responses
- Large quantity of complex data
- ✓ SmPCs comparison
- ✓ Medical practice/healthcare infrastructure
- ✓ Clinical context
- ✓ Alternative therapeutic options





Available at www.scopejointaction.eu

Recommendations ADSs



- The identification of ADS solely is not sufficient to ensure applicability of ADSs in routine PV practices
- Better definition of ADSs applicability for PV purposes (ADS validation for use in PV procedures assessment)



A specific examples from ES, IT and UK of the useful experience with additional data sources have been received in the survey describing consolidated practice with ADSs (included in the Topic 1 Recommendations document – as a part or training material package).



NEED TO INCREASE AWARNESS IN THIS AREA Specific presentations included in the training course (HC databases, ADSs for evaluation of vaccine and pregnancy exposure safety issues) Training materials and other useful tools for PV assessors



Competence is the ability of an individual to do job successfully and efficiently

•Implementation of **quality system** (e.g. SOPs, mentoring system, introduction programme, obligatory trainings) for newly employed assessors and for maintenance of assessors' knowledge.


• Implementation of **continuing professional development programmes**, personal educational forms (a format that allows recording of attended trainings) for the motivation of assessors' participation in training events.



THE EXCHANGE PROGRAM FOR ASSESSORS - Proof of concept grounds for a sustainable exchange programme for European PV assessors

Deliverables – RMP, PASS, PSUR and referral topics





Deliverables- Practical guides



WP8 Practical guidance in addition to formal regulatory documents and national SOPs

- Not to replace existing guidance (GVPs)
- Not intended to advise on procedural aspects or to influence templates and guiding text provided by EMA


The guidance are based on

- Responses to a WP8 survey in 2014 to NCAs on current practices, challenges and solutions
- Practical experiences in European procedures





Deliverables- Practical guides



- Key challenges and learnings from PRAC on handling PV procedures assessment
- Practical advice <u>on some aspects</u>
- "From assessors for assessors"
- Planning time and resources
- Getting the scope right
- Value of Expert Advice
- Delivering the consistant asessment report/package

Specific for referral:

- Oral explanations
- Public hearings



Available at www.scopejointaction.eu

Deliverables: Training course

SCOPE

to share experience and practical advice

Opportunity for exchange of ideas

to increase the awareness on some specific aspects of PV

to learn more from each other and to increase consistency in our work

to discover new tools that could facilitate the assessment of PV procedures



123 participants From 26 MS and 3 from EMA 20 speakers from 9 MS



Work Package 8 Lifecycle Pharmacovigilance Final Training Lisbon, 20 and 21 September 2016 50 % reply rate to the evaluation questionnaire 18 MS

Deliverables: e-learning modules

- RMP
- PASS
- PSUR/PSUSA
- referral





.....to maximise training opportunities for PV assessors





Select here to access your bank of resources for this e-learning



Help: Select here for help on how to use the screens



Exit button: Select here to exit the course at any time



Page counter example: This will tell you what page you are on, and how many you have left

Forward and back arrows: Use these arrows to navigate backwards and forwards through the course

https://www.walkgroveonline.com/MH RA/WP8/wp8sr gold 2/story.html




Key stages in the referral procedure

Key stages and other important considerations

This interactive timeline illustrates key stages and other important considerations during a referral from an assessor's perspective. Click on the stages to jump to the relevant section.

Select each of the stages to find out more.



What is the purpose of a safety referral (article 20, article 107i, article 31)?

That's still not quite right, the correct answers are highlighted.

A more appropriate way of harmonising the SmPC and PIL between nationally-authorised products in all member states would through an article 30 referral procedure.

Requesting additional data is a possible outcome of a referral but is not generally the reason for triggering one.

Resolving differences of opinion between MS raised during a safety variation assessment should be done via an article 13 referral arbitration procedure.article 13 referral arbitration procedure.

e e ? ×

authorised products in all member states

To establish if additional data would be useful to support the positive B/R balance of the product

To resolve issues over the safety or balance of benefits and risks of a medicine or class of medicines

To establish whether measures to minimise harm to patients are required throughout Europe

To resolve differences in opinion between MS raised during a safety variation assessment


To establish whether the MA for a product or group of products should to be varied, maintained, suspended or revoked in the light of concerns about safety or the balance of benefits and risks

03 01

Benefits for EU PV network



- Contribution to EU Pharmacovigilance Training Curriculum
- Maximizing of training opportunities for PV assessors (e.g e-learning moduls)
- Identification of areas where more commitment is needed (e.g use of ADSs and evaluation of effectiveness of RMMs)
- Promotion of consistent PV procedures assessment
- Evaluation of the quality of assessment provided by WP7 and presented also in WP8 training
- Promotion of collaboration among NCAs and MS



Ingebjorg Buajordet (NO) – topic 2 lead

Niamh Buckley (IE) Eleanor Carey (IE) Leonor Chambel (PT) Maria Consuelo Cicalese (IT) Virginia Cuconato (IT) Marco Di Girolamo (IT) Yvette Escudero (ES) Mick Foy (UK) Rolf Gedeborg (SE) Margarida Guimaraes (PT) Jelena Ivanovic (IT) – topics 1,4,5 lead Karl Mikael Kälkner (SE) Louise Loughlin (UK) Miguel Ángel Macia (ES) Elena Marotta (IT) Ana Martins (PT) **Dolores Montero (ES)** Gunnar Rimul (NO) Anja Schiel (NO) Eva Segovia (ES) Alison Shaw (UK) Almath Spooner (IE) Annika Wennberg (SE) Jane Woolley (UK) Qun-Ying Yue (SE) – topic 3 lead



Questions?

Contact: Jelena Ivanovic, MD, PhD Italian Medicines Agency j.ivanovic@aifa.gov.it





Now this is not the end. It is not even the beginning of the end But it is, performed of ining.

on Churchill